In LNCaP cells enhanced expression of the androgen receptor compensates for Bcl-2 suppression by antisense oligonucleotides

Therapeutic Advances in Urology

Volumn 3, Issue 2, 2011, Pages 51-57

  Rubenstein, Marvin ^a   Hollowell, Courtney M p ^b   Guinan, Patrick ^c  

^a Hektoen Institute for Medical Research   (United States)

^b Jr Hospital of Cook County   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

antisense; interferon; prostate cancer; therapy

Indexed keywords

ANDROGEN RECEPTOR; ANTISENSE OLIGONUCLEOTIDE; APOPTOSIS INHIBITOR; CASPASE 3; PROTEIN BCL 2;

ANTISENSE THERAPY; APOPTOSIS; ARTICLE; CELL STRAIN LNCAP; CELL SURVIVAL; CONTROLLED STUDY; HORMONE SENSITIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH;

EID: 79959188587     PISSN: 17562872     EISSN: 17562880     Source Type: Journal    
DOI: 10.1177/1756287211400493     Document Type: Article

References (11)

1. Eder I.E. Culig Z. Ramoner R. Thurnher M. Putz T. Nessler-Menardi C. (2000) Inhibition of LNCaP prostate cancer cells by means of androgen receptor antisense oligonucleotides. Cancer Gene Therapy 7: 997–1007.
2. Huang H. Cheville J.C. Pan Y. Roche P.C. Schmidt L.J. Tindall D.J. (2001) PTEN induces chemosensitivity in PTEN-mutated prostate cancer cells by suppression of BCL-2 expression. J Biol Chem 276: 38830–38836.
3. Kling J. (2010) Safety signal dampens reception for mipomersen antisense. Nat Biotechnol 28: 295–297.
4. Mu Z. Hachem P. Pollack A. (2005) Antisense Bcl-2 sensitizes prostate cancer cells to radiation. Prostate 65: 331–340.
5. Pandini G. Mineo R. Frasca F. Roberts C.T. Jr Marcelli M. Vigneri R. (2005) Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells. Cancer Res 65: 1849–1857.
6. Rubenstein M. Anderson K.M. Tsui P. Guinan P. (2006) Synthesis of branched antisense oligonucleotides having multiple specificities: Treatment of hormone insensitive prostate cancer. Med Hypoth 67: 1375–1380.
7. Rubenstein M. Dunea G. Guinan P. (1994) Growth factor deprivation therapy utilizing antisense oligonucleotides. Drug News Perspect 7: 517–524.
8. Rubenstein M. Guinan P. (2010) Bispecific antisense oligonucleotides have activity comparable to monospecifics in inhibiting expression of Bcl-2 in LNCaP cells. In Vivo 24: 489–493.
9. Rubenstein M. Mirochnik Y. Bremer E. George D. Freilich L. Guinan P. (2002) Inhibitory effect of antisense oligonucleotides targeting epidermal growth factor receptor may not be related to changes in mRNA levels in human prostate carcinoma cells. Proc AACR 43: 590a–590a.
10. Rubenstein M. Tsui P. Guinan P. (2010) treatment of prostate and breast tumors employing mono- and bispecific antisense oligonucleotides targeting apoptosis inhibitory proteins clusterin and Bcl-2. Med Oncol 27: 592–599.
11. Yip K.W. Mocanu J.D. Au P.Y. Sleep G.T. Busson D. Yeh P. (2005) Combination Bcl-2 antisense and radiation therapy for nasopharyngeal cancer. Clin Cancer Res 11: 8131–8144.